Novartis Pursuit of Cytokinetics Cools | EUROtoday

Get real time updates directly on you device, subscribe now.

Jan. 11, 2024 12:19 pm ET

Novartis has backed away from its pursuit of Cytokineticsplacing a damper on the prospects of a deal for the promising heart-drug developer.

The Swiss drug large had been closing in on a purchase order of South San Francisco-based Cytokinetics, with an settlement anticipated as quickly as this week, The Wall Street Journal reported Monday. But Novartis, which had been pursuing the biotech for a number of months, backed away someday up to now day or two, in line with the folks.

Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8